About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

The Gilenya Pregnancy Registry

NCT01285479·61 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Novartis Pharmaceuticals

Age

Any age

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Any woman with a diagnosis of MS
Any woman currently pregnant
Exposure to fingolimod during pregnancy or up to 8 weeks before LMP
Signed informed consent

The record

StatusCompleted

PhaseNo phase

Taking part312

StartedOct 2011

UpdatedJan 22, 2025

Conditions

Multiple Sclerosis

Where61

Novartis Investigative Site
Fort Lauderdale, Florida, United States
Novartis Investigative Site
Cambridge, Massachusetts, United States
Novartis Investigative Site
Grand Forks, North Dakota, United States

Clareo Health | The Gilenya Pregnancy Registry